IMM0306

DRUG4 trials

Sponsors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Conditions

B-cell Non-Hodgkin's LymphomaCD20-positive B-cell Non-Hodgkin's LymphomaIgG4-Related Disease

Phase 1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

SuspendedNCT04746131

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.B-cell Non-Hodgkin's Lymphoma

Start: 2021-01-15End: 2024-04-11Target: 90Updated: 2022-09-26

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.B-cell Non-Hodgkin's Lymphoma

Start: 2023-05-31End: 2025-11-30Target: 102Updated: 2023-05-24

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.CD20-positive B-cell Non-Hodgkin's Lymphoma

Start: 2020-03-02End: 2025-05-25Target: 154Updated: 2023-04-10

Phase 2

A Study of IMM0306 in IgG4-Related Disease

Not yet recruitingNCT07621939

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.IgG4-Related Disease

Start: 2026-07-01End: 2030-05-01Target: 125Updated: 2026-06-02

Related Papers

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Blood2025-11-03

Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.

Journal of Clinical Oncology2025-05-28

Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.

2024-12-182 citations

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Blood2024-11-051 citations

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Blood2024-11-05

Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Journal of Clinical Oncology2024-06-012 citations

Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT173: Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma

Cancer Research2024-04-051 citations